The Global Recombinant Proteins Market was valued at USD 2.5 billion in 2025 and is estimated to grow at a CAGR of 9.3% to reach USD 5.7 billion by 2035.
Growth is driven by the increasing use of therapeutic proteins in treating chronic and life-threatening conditions, including cancer, diabetes, and autoimmune diseases. A rising global geriatric population, along with a higher burden of chronic illnesses, is further accelerating demand for innovative treatment approaches. Recombinant proteins are engineered through DNA recombination techniques and produced using host systems such as bacterial, yeast, or mammalian cells, enabling large-scale production of targeted proteins that are otherwise difficult to extract naturally. These proteins are widely applied across therapeutics, diagnostics, and research activities due to their precision, scalability, and reliability. Continuous advancements in biotechnology, combined with expanding applications in drug development and personalized medicine, are strengthening their importance in modern healthcare systems. Increasing investment in research infrastructure and growing adoption of biologics are further reinforcing market growth.
The products segment reached USD 1.6 billion in 2025. Strong demand is supported by the widespread use of recombinant proteins across pharmaceutical, biotechnology, and research applications. Growing reliance on biologic-based therapies is further driving product adoption. Continuous improvements in protein engineering are also enabling the development of more stable and functionally enhanced protein products, supporting sustained market dominance.
The drug discovery and development segment held 34.3% share in 2025. This segment includes biologics, vaccines, and cell and gene therapy applications. Recombinant proteins are widely used in multiple stages of drug development, including target identification, validation, and clinical evaluation. Their role in studying biological mechanisms and supporting therapeutic innovation is driving strong demand. Increasing focus on personalized treatment approaches, along with rising chronic disease prevalence, is further strengthening the importance of recombinant proteins in pharmaceutical research and development activities.
North America Recombinant Proteins Market accounted for 48.4% share in 2025, maintaining its leading position. The region benefits from a strong biotechnology and pharmaceutical ecosystem that supports innovation in protein-based therapies. A well-established healthcare infrastructure and high prevalence of chronic diseases continue to drive demand for advanced treatment solutions. Strong regulatory systems, along with significant investment in research and development, further support market expansion. Growing emphasis on precision medicine is also contributing to sustained regional growth.
Key companies operating in the Global Recombinant Proteins Market include Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), GenScript Biotech, Bio-Techne, Sino Biological, ACROBiosystems Group, Abnova, Proteintech Group, RayBiotech, Creative BioMart, BPS Bioscience, ProteoGenix, Bio-Rad Laboratories, and Miltenyi Biotec. Companies in the Recombinant Proteins Market are strengthening their position through continuous innovation in protein engineering and expansion of product portfolios. They are investing in advanced manufacturing technologies to improve production efficiency and scalability. Strategic collaborations with pharmaceutical and biotechnology firms are enhancing research capabilities and accelerating product development. Many players are focusing on expanding their global distribution networks to improve market access. In addition, companies are increasing investment in GMP-compliant production facilities to ensure product quality and regulatory compliance.
This product will be delivered within 2-4 business days.
Growth is driven by the increasing use of therapeutic proteins in treating chronic and life-threatening conditions, including cancer, diabetes, and autoimmune diseases. A rising global geriatric population, along with a higher burden of chronic illnesses, is further accelerating demand for innovative treatment approaches. Recombinant proteins are engineered through DNA recombination techniques and produced using host systems such as bacterial, yeast, or mammalian cells, enabling large-scale production of targeted proteins that are otherwise difficult to extract naturally. These proteins are widely applied across therapeutics, diagnostics, and research activities due to their precision, scalability, and reliability. Continuous advancements in biotechnology, combined with expanding applications in drug development and personalized medicine, are strengthening their importance in modern healthcare systems. Increasing investment in research infrastructure and growing adoption of biologics are further reinforcing market growth.
The products segment reached USD 1.6 billion in 2025. Strong demand is supported by the widespread use of recombinant proteins across pharmaceutical, biotechnology, and research applications. Growing reliance on biologic-based therapies is further driving product adoption. Continuous improvements in protein engineering are also enabling the development of more stable and functionally enhanced protein products, supporting sustained market dominance.
The drug discovery and development segment held 34.3% share in 2025. This segment includes biologics, vaccines, and cell and gene therapy applications. Recombinant proteins are widely used in multiple stages of drug development, including target identification, validation, and clinical evaluation. Their role in studying biological mechanisms and supporting therapeutic innovation is driving strong demand. Increasing focus on personalized treatment approaches, along with rising chronic disease prevalence, is further strengthening the importance of recombinant proteins in pharmaceutical research and development activities.
North America Recombinant Proteins Market accounted for 48.4% share in 2025, maintaining its leading position. The region benefits from a strong biotechnology and pharmaceutical ecosystem that supports innovation in protein-based therapies. A well-established healthcare infrastructure and high prevalence of chronic diseases continue to drive demand for advanced treatment solutions. Strong regulatory systems, along with significant investment in research and development, further support market expansion. Growing emphasis on precision medicine is also contributing to sustained regional growth.
Key companies operating in the Global Recombinant Proteins Market include Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), GenScript Biotech, Bio-Techne, Sino Biological, ACROBiosystems Group, Abnova, Proteintech Group, RayBiotech, Creative BioMart, BPS Bioscience, ProteoGenix, Bio-Rad Laboratories, and Miltenyi Biotec. Companies in the Recombinant Proteins Market are strengthening their position through continuous innovation in protein engineering and expansion of product portfolios. They are investing in advanced manufacturing technologies to improve production efficiency and scalability. Strategic collaborations with pharmaceutical and biotechnology firms are enhancing research capabilities and accelerating product development. Many players are focusing on expanding their global distribution networks to improve market access. In addition, companies are increasing investment in GMP-compliant production facilities to ensure product quality and regulatory compliance.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Products & Services, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Host-cell, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 10 Company Profiles
Companies Mentioned
The companies profiled in this Recombinant Proteins market report include:- Abnova
- ACROBiosystems Group
- Bio Rad Laboratories
- Bio Techne
- BPS Bioscience
- Creative BioMart
- GenScript Biotech
- Merck KGaA (MilliporeSigma)
- Miltenyi Biotec
- Proteintech Group
- ProteoGenix
- RayBiotech
- Sino Biological
- Thermo Fisher Scientific
